Physician profile
Joseph Lamar
NPI 1073928883
$4,344.90
in general payments reported to CMS, 2019-2025
27 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $1,444 · 2023: $1,088 · 2024: $1,141 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338 · Travel and Lodging: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.35 |
| Travel and Lodging | $439.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,038.92 | 2022 | |
| Intuitive Surgical, INC. | $566.98 | 2023-2025 | Da Vinci Surgical System |
| Regeneron Healthcare Solutions, INC. | $323.77 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $275.70 | 2021-2025 | Airsupra, Fasenra, Breztri |
| Medical Device Business Services, INC. | $251.48 | 2024 | Monarch |
| Olympus America INC. | $230.44 | 2022-2025 | Spiration Valve System |
| Ethicon INC. | $186.93 | 2024-2025 | Monarch Platform |
| Glaxosmithkline, LLC. | $179.79 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Medtronic, INC. | $149.16 | 2023 | Illumisite |
| Steris Corporation | $136.81 | 2025 | |
| Dompe US, INC. | $124.20 | 2024 | Oxervate |
| Actelion Pharmaceuticals US, INC. | $97.78 | 2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $88.02 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $83.83 | 2023-2025 | Glassia |
| Ani Pharmaceuticals, INC. | $81.60 | 2024-2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.95 | 2023-2024 | Ofev |
| Insmed, INC. | $73.88 | 2023-2025 | Arikayce |
| Baxter Healthcare | $67.66 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $63.32 | 2022-2024 | |
| Pulmonx Corporation | $61.38 | 2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| United Therapeutics Corporation | $43.47 | 2022-2024 | Tyvaso |
| Amgen INC. | $39.85 | 2023-2024 | Tezspire |
| Biomerieux INC | $29.67 | 2023 | |
| Astellas Pharma US INC | $23.22 | 2022 | |
| Grifols USA, LLC | $20.84 | 2024 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $16.03 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $14.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.